Patents by Inventor Dennis A. Emma

Dennis A. Emma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240157631
    Abstract: The present disclosure includes a multi-fluid kit for three-dimensional printing. The multi-fluid kit can include a fusing agent comprising water and a radiation absorber that absorbs radiation energy and converts the radiation energy to heat, an acidic agent having a pH from about pH 1 to about pH 6.9 that includes water and an acidic component, and a pore-promoting agent including water and a pore-promoting compound. The pore-promoting compound can chemically react with the acidic component to generate a gas, and can be selected from sodium bicarbonate, potassium bicarbonate, or a combination thereof.
    Type: Application
    Filed: March 12, 2021
    Publication date: May 16, 2024
    Inventors: Emre Hiro DISCEKICI, Shannon Reuben WOODRUFF, Dennis J. SCHISSLER, Graciela Emma NEGRI JIMENEZ
  • Publication number: 20100222262
    Abstract: Compositions and methods for reducing cardiovascular risk utilizing substituted 1,3-cyclopentadione compounds are described.
    Type: Application
    Filed: April 2, 2009
    Publication date: September 2, 2010
    Applicant: METAPROTEOMICS, LLC
    Inventors: Veera Konda, Anu Desai, Matthew L. Tripp, Gary K. Darland, Joseph Lamb, Jeffrey S. Bland, Dennis A. Emma
  • Publication number: 20100137449
    Abstract: Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.
    Type: Application
    Filed: December 10, 2008
    Publication date: June 3, 2010
    Applicant: METAPROTEOMICS, LLC
    Inventors: Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Veera Konda, Anu Desai, Gary Darland, Brian J. Carroll, James S. Traub, Linda M. Pacioretty, Dennis Emma
  • Patent number: 6037520
    Abstract: An adherent, stable, continuous human breast carcinoma cell line (GI-101A) has been produced from an infiltrating ductal breast carcinoma xenograft (GI-101) which has been grown and maintained in athymic mice for the past nine years. The GI-101A cells grow with an average doubling time of about 48 to about 72 hours. The cells display antigenic determinants consistent with those of the human breast tumor xenograft (GI-101) from which it was derived. The cell line, GI-101A, when injected subcutaneously into the subaxial area of athymic animals, such as athymic mice, produces tumors that spontaneously metastasize to distant organ sites, such as the lungs and lymph nodes. The cell line and the tumors that it produces may be used as model systems for study mechanisms responsible for metastatic behavior and for testing for new as well as screening for effective new anti-cancer drug therapies.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: March 14, 2000
    Assignee: Goodwin Institute for Cancer Research
    Inventors: Shula Raney, Dennis Emma, Josephine Hurst
  • Patent number: 5693533
    Abstract: An adherent, stable, continuous human breast carcinoma cell line (GI-101A) has been produced from an infiltrating ductal breast carcinoma xenograft (GI-101) which has been grown and maintained in athymic mice for the past nine years. The GI-101A cells grow with an average doubling time of about 48 to about 72 hours. The cells display antigenic determinants consistent with those of the human breast tumor xenograft (GI-101) from which it was derived. The cell line, GI-101A, when injected subcutaneously into the subaxial area of athymic animals, such as athymic mice, produces tumors that spontaneously metastasize to distant organ sites, such as the lungs and lymph nodes. The cell line and the tumors that it produces may be used as model systems for study mechanisms responsible for metastatic behavior and for testing for new as well as screening for effective new anti-cancer drug therapies.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: December 2, 1997
    Assignee: The Goodwin Institue for Cancer Research
    Inventors: Shula Raney, Dennis Emma, Josephine Hurst